drugset / Trial / NCT04860661

Esketamine on Postpartum Depression in Cesarean Section Women

NCT04860661

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug

Timeline

Start
2021-05-01
Primary completion
2024-03-31
Completion
2024-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 80 mg Intravenous

Indications